New Delhi, Feb 3 The trade deal between India and the US is a game-changer for the Indian MedTech and pharma sectors, said industry experts on Tuesday.
In a historic move, the US has announced a reduction in tariffs on Indian exports to 18 per cent from 50 per cent, which is a constructive development for the India-US trade relations.
The US is India’s largest export destination, accounting for about 20 per cent of total exports.
The Association of Indian Medical Devices (AiMeD), hailed the deal and noted that it can prove to be a “vital boost for our manufacturers, enhancing global competitiveness, spurring investments, and creating jobs”.
“The US tariff slash from 50 per cent to 18 per cent is a game-changer for Indian medical devices, slashing export costs and unlocking billions in US market potential amid China+1 shifts. We urge sustained India-US regulatory harmonisation to capitalise fully on this opportunity for ‘Make in India’ MedTech success,” said Rajiv Nath, Forum Coordinator, AiMeD.
Further, Nath noted that the US tariff cut to 18 per cent on Indian goods also provides Indian medical devices a competitive edge over Chinese counterparts, which face higher Section 301 tariffs typically at 25 per cent plus additional hikes (up to 50-60 per cent on some items like respirators).
“Previously, India endured up to 50 per cent duties while China had around 30 per cent, but the new deal aligns India’s rate below China’s base, favouring India amid China+1 diversification,” he added.
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) also highlighted the positive implications of the India-US trade deal for the Indian pharma sector.
“The India-US trade agreement represents a pivotal moment for the pharmaceutical sector, with key highlights including the reduction of tariffs on Indian goods exports,” said Namit Joshi, Chairman – Pharmexcil.
“The reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market, which accounts for 30-40 per cent of the sector's total revenue,” he added.
Joshi noted that the deal also fosters greater market access for Indian generics and biosimilars, strengthening India’s position as the global leader in affordable medicines.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor